Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1358

IBI334-B7H3-hIgG1

Home » Antibodies » IBI334-B7H3-hIgG1

Background of IBI334-B7H3-hIgG1

EGFR is a tyrosine kinase receptor that plays a vital role in cell proliferation, differentiation, and survival through essential signaling pathways. Abnormal EGFR signaling can cause excessive cell growth and the formation of tumors. Conversely, B7-H3 is an immune checkpoint molecule that primarily inhibits the activation and expansion of T cells, thus preventing an overactive immune response. EGFR/B7-H3 dual antibodies are targeted drugs that specifically target these two molecules. They function by inhibiting EGFR signaling to impede tumor cell proliferation and by blocking B7-H3 signaling to activate T cells, thereby enhancing their ability to attack tumor cells. Consequently, the primary mechanism of action of EGFR/B7-H3 dual antibody therapy is to simultaneously inhibit tumor growth and enhance the immune system's ability to kill, resulting in a dual assault on tumors.

Specifications

Catalog Number:
KB-1358
Antibody Name:
IBI334-B7H3-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
B7H3
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Next‐generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non‐small cell lung cancer.
  2. Zhao Q, Liu J, Yang S. Therapeutically targeting B7-H3 via chimeric antigen receptors and bispecific killer cell engagers in non-small cell lung cancer. Journal of Immunology. 2018:200.